Chronic Liver Disease Protocol

HepaticModerate Evidence

supplements

Primary

Supporting

Grade A

Studies

Primary Stack

Core supplements with strongest evidence

Silymarin (Milk Thistle)B

420mg daily (standardized to 70-80% silymarin)

Flavonoid complex with hepatoprotective, antioxidant, and antifibrotic properties

18 studies1,200 participants

Supporting Studies (1)

PMID: 28219059 - Silymarin in liver diseases: a systematic review (2017)

S-Adenosyl-L-Methionine (SAMe)B

1200mg daily in divided doses

Methyl donor that supports glutathione synthesis and hepatocyte membrane integrity

12 studies650 participants

Supporting Studies (1)

PMID: 12406603 - SAMe for alcoholic liver disease (2002)

Supporting Stack

Additional supplements for enhanced results

N-Acetyl Cysteine (NAC)B

1200-1800mg daily

Glutathione precursor that reduces oxidative stress and supports detoxification

8 studies380 participants

Vitamin EA

800 IU daily

Antioxidant that reduces lipid peroxidation; studied in NASH/NAFLD

All-Cause Mortality↑High-density lipoprotein (HDL)↓Insulin Resistance↓Triglycerides↑Insulin

10 studies850 participants

Supporting Studies (1)

PMID: 20427778 - PIVENS trial: Vitamin E in NASH (2010)

PhosphatidylcholineC

1800mg daily

Essential phospholipid for hepatocyte membrane repair and bile secretion

5 studies220 participants

ZincB

30-50mg daily

Often deficient in liver disease; supports alcohol dehydrogenase and immune function

6 studies280 participants

How This Protocol Works

Simple Explanation

Chronic liver disease involves ongoing inflammation, oxidative stress, and progressive scarring (fibrosis) that impairs the liver's ability to detoxify and metabolize. This protocol supports liver protection and regeneration.

•Milk thistle (silymarin) is the most studied liver supplement. It stabilizes hepatocyte membranes, increases glutathione levels, and has anti-inflammatory effects. Studies show it can improve liver enzymes and potentially slow fibrosis.

•SAMe is a natural compound involved in methylation and glutathione production. The liver normally makes SAMe, but this is impaired in liver disease. Supplementation supports detoxification pathways.

•NAC provides cysteine for glutathione synthesis—the liver's master antioxidant. It's used medically for acetaminophen overdose and supports general liver detoxification.

•Vitamin E (800 IU) is the only supplement with Level A evidence in NAFLD/NASH from the PIVENS trial, showing histological improvement.

•Phosphatidylcholine helps repair damaged cell membranes and supports bile flow.

•Zinc deficiency is common in liver disease and worsens outcomes.

Important: Work with your hepatologist. Avoid high-dose vitamin A, iron (unless deficient), and limit acetaminophen.

Expected timeline: Liver enzyme improvements may be seen in 8-12 weeks. Histological changes take 6-12 months.

Clinical Perspective

Chronic liver disease pathophysiology involves hepatocyte injury, Kupffer cell activation, stellate cell transformation to myofibroblasts, and progressive fibrosis. Oxidative stress and glutathione depletion are central mechanisms.

•Silymarin (B-grade): Flavonolignan complex (silybin, silydianin, silychristin). Mechanisms: membrane stabilization, free radical scavenging, Nrf2 activation, NF-κB inhibition, antifibrotic effects via TGF-β reduction. Meta-analyses show ALT/AST reduction; mortality benefit in alcoholic cirrhosis subgroups (PMID: 28219059).

•SAMe (B-grade): Methyl donor for transsulfuration pathway producing glutathione. Improves membrane fluidity via phosphatidylcholine synthesis. Meta-analysis showed mortality/transplant benefit in less severe alcoholic liver disease (PMID: 12406603).

•NAC (B-grade): Rate-limiting precursor for glutathione. Used in acetaminophen toxicity. Studies in alcoholic hepatitis and NAFLD show improved liver function tests and oxidative markers.

•Vitamin E (A-grade): PIVENS trial (PMID: 20427778): 800 IU α-tocopherol improved histology in NASH (43% vs 19% placebo, p=0.001). Reduces lipid peroxidation and stellate cell activation. Concern: meta-analyses suggest increased all-cause mortality at >400 IU, but liver benefit may outweigh in NASH.

•Phosphatidylcholine (C-grade): Essential membrane phospholipid. Supports bile flow and hepatocyte integrity. Some evidence in alcoholic liver disease.

•Zinc (B-grade): Deficient in 30-60% of cirrhotics due to malabsorption and increased urinary loss. Required for alcohol dehydrogenase, superoxide dismutase. Improves encephalopathy markers.

Monitoring: LFTs (ALT, AST, GGT, ALP), bilirubin, albumin, INR, platelet count, FibroScan/elastography.

Cautions: Avoid in decompensated cirrhosis without hepatology guidance. Drug interactions possible.

View All Protocols